Hydron Technologies, Inc. and Brand Builders International, LLC Join Forces to Form ... ( DELRAY BEACH Fla. Nov. 11 /- Hydr...)

Hydron Technologies, Inc. and Brand Builders International, LLC Join Forces to Form New Entity

Date:11/11/2008

DELRAY BEACH, Fla., Nov. 11 /PRNewswire-FirstCall/ -- Hydron Technologies, Inc. (OTC Bulletin Board: HTEC) announced today that it has entered in to agreement with Brand Builders International, LLC, a private marketing firm, to form a join venture called Brand Builders Rx, LLC.

Hydron Technologies has been developing products for healthcare professionals for over 50 years. Hydron introduced the only non-occlusive polymer that binds moisture and other ingredients to the skin, while allowing the skin to breathe. This technology is used by various companies in soft contact lenses, burn and wound dressings, topical drug delivery and subcutaneous implants that deliver cancer treating drugs and more. Hydron has also been awarded a patent on the first volatile emulsifier that allows products to self-adjust to each individual.

Brand Builders International was founded by Ilonka Harezi, the driving force behind Teslar Technology and the world famous Philip Stein Teslar watches. These watches were selected twice as one of Oprah Winfrey's top ten favorite gifts and generated over $97 million in retail sales in 2007. Today, Brand Builders International leverages Ms. Harezi's experience in sales and marketing to help companies build distribution domestically and globally.

The new Joint Venture, Brand Builders Rx, will combine the expertise of the two entities for the re-positioning and re-launching of the Hydron named brands, utilizing the marketing and distribution expertise of Ilonka Harezi, her success with the Teslar brand and her Brand Builders International team. The Joint Venture expects to build brand awareness and increase distribution during the first two years, with a projected profit expected in year three.

Under the terms of the Agreement, Hydron will contribute substantially all of its operating assets and license to the Joint Venture the patented technologies, while Brand Builders International will contribute cash, financing, new
'/>"/>

SOURCE Hydron Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. JZZ Technologies, Inc. Announces 3rd Quarter Results Date
2. Wound Management Technologies, Inc. Announces Strategic Business Directions, Recent Conference Presentation, in Addition to Symposium Exhibit Plans for Las Vegas
3. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
4. Sigma Breakthrough Technologies, Inc. (SBTI) Is Expanding Its Service Offering for Global Clients by Announcing the Public Listing of SBTI Europe GmbH
5. VirtualHealth Technologies, Inc., Announces That Its Associate, Private Access, Will Be Partnering with Genetic Alliance To Accelerate Medical Research While Protecting Privacy
6. VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO
7. Wound Management Technologies, Inc. Announces Clarification of Eprint Viewing of Case Report in Advances in Skin and Wound Journal
8. Wound Management Technologies, Inc. Announces Products to Be Registered in Taiwan
9. SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride
10. Wound Management Technologies, Inc. Announces Filing of a 510K
11. VNUS Medical Technologies, Inc. Announces Board of Director Resignation

Post Your Comments:

(Date:5/21/2013)... May 21, 2013 ContinuCare Home Health, ... Department of Aging and Disability Services. After completing a ... interviews, ContinuCare Home Health was found to have ... is part of the Department of Aging and Disability ... and disability services, supports and opportunities that are ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Artisan ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, ... will focus on exploring alternative finance through EB-5 ... latest market, legal and economic information, and updates ... legal professionals within the EB-5 industry. , ...

(Date:5/21/2013)... May 21, 2013 According to a May ... the Use of Botox,” Botox injections have become ... approval in 2002 (Go to goo.gl/8iYbD). Although it is mostly ... with men. The injection makes facial wrinkles less visible by ... last for about three months. This means that people who ...

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...

(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...

Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis

... Boston Scientific,Corporation (NYSE: BSX ) today announced ... ALTRUA(TM) family of pacemakers. ALTRUA is Boston,Scientific,s most ... small size and battery longevity. It is the ... in which the,heart beats too slowly -- usually ...

... Inc.,("GNC" or the "Company"), the largest global specialty ... for the first,quarter ended March 31, 2008., ... of GNC Parent LLC,which was acquired on March ... and Ontario Teachers, Pension Plan Board ("Teachers"). As ...

... Alimera Sciences Inc., a privately held,ophthalmic pharmaceutical ... pilot study to assess the safety and efficacy ... Genentech) in patients,with exudative age-related macular degeneration (wet ... performed under an investigator,sponsored IND, will compare two ...

... Market Share in Europe and Canada; ... LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. ... first quarter ended March,31, 2008. All figures are in ... to make strong progress in the global,commercialization of our ...

... Appeals for More than $8 million for medicines and other lifesaving ... ... As the death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely ... sanitary conditions,could significantly increase the death toll among children and other,vulnerable populations, ...

... Inc. ("Holdings",or the "Company"), the parent company of ... largest cancer services companies, reported revenue of,$810.6 million, ... flow of,$50.9 million for the quarter ended March ... those of US Oncology, its wholly-owned,subsidiary, through which ...

Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)Labopharm Reports Results for First Quarter Fiscal 2008 Myanmar Cyclone a Children's Catastrophe - UNICEF US Oncology Reports First Quarter 2008 Results

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

(Date:5/21/2013)... CEO of Mammotome, a division of Devicor Medical Products, has ... Cincinnati chapter of the Association for Corporate Growth ... who is also a breast cancer survivor, led the purchase ... 2010. Daulton will be presented with the award at the ... May 22. The ACG Deal Maker Awards program ...

(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... ZURICH, July 16 An innovative treatment ... patients has received a second,orphan drug designation in ... was,granted. The recent designation relates to Burkholderia cepacia ... patients. For Axentis,Pharma AG of Zurich, Switzerland, both ...

... , BOSTON and EDISON, N.J., July ... with edoxaban(2) - an investigational oral Factor Xa inhibitor - ... receiving edoxaban once daily (QD) experienced fewer bleeding events than ... that bleeding associated with edoxaban is most closely correlated with ...

Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2 Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Pelvic Washing for Cytology PBG, Urine Quantitative Parvovirus B19 Antibody, IgM Parvovirus B 19, by PCR, Bone Marrow